Developer docs
API playgroundTry for free, no card

Search company profiles

Nemera

Full company profile

uuid00076bq

Namestring
Nemera
Legal namestring
Financiere N
Websiteurl
nemera.net
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Nemera is a France-headquartered, privately held contract development and manufacturing organization (CDMO) specializing in drug delivery device solutions across ophthalmic, parenteral, inhalation, dermal, ear-nose-throat, oral, and intimate care administration routes. The company designs, develops, and manufactures proprietary device platforms — including the Novelia multi-dose eyedropper system with patented PureFlow silicone membrane technology, Safe'n'Sound passive needle safety devices, Symbioze on-body wearable injectors for high-viscosity biologics, Sof'Bag+ airless dermal packaging, and DPI/pMDI inhalers — alongside tailor-made pen injectors and auto-injectors. Manufacturing is conducted across five GMP-certified sites in France, Germany, Poland, the United States, and Brazil, encompassing over 42,000 square meters of clean room capacity and producing more than one billion devices annually for distribution in 54 countries.

The company operates a hybrid B2B business model combining project-based combination product development services (front-end innovation, human factors, design verification, regulatory strategy) with proprietary product sales and contract manufacturing across clinical and commercial volumes. Customers are large pharmaceutical, biotechnology, and generic drug companies — disclosed enterprise relationships include GlaxoSmithKline, SciGen, and Haohai Qisheng. Pricing is negotiated per-project under multi-year contracts and is not publicly disclosed. The Insight Innovation Center in Chicago houses over 200 innovation and device development consultants serving as Nemera's front-end innovation engine.

Nemera is jointly owned by private equity firms Montagu and Astorg (with LGT Capital Partners as a co-investor), and traces its corporate history to Rexam Healthcare before being acquired by Montagu in 2014. The company has pursued a sustained buy-and-build strategy (Insight Product Development in 2019, Copernicus in 2020, Milfra in 2021) and has stated a strategic ambition to become a billion-dollar company by 2030. The company maintains comprehensive quality certifications including ISO 13485, EU MDR, FDA 21 CFR Part 820, MDSAP, and EcoVadis Gold status for sustainability.

Short descriptiontext

Nemera is a France-headquartered, PE-backed CDMO designing and manufacturing proprietary drug delivery devices — eyedroppers, injectors, inhalers, and nasal systems — for global pharmaceutical, biotech, and generics customers across five manufacturing sites serving 54 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug delivery devices, contract manufacturing services, combination product development, ophthalmic drug delivery, parenteral injection devices
Industry5 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Drug Delivery Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Manufacturing Services
TypeProfessional Services
Description

Nemera provides contract development and manufacturing services for drug delivery devices and combination products. This includes clinical and commercial manufacturing, process engineering, and industrialization services. Revenue is generated through project-based contracts and long-term manufacturing partnerships with pharmaceutical companies.

nemera.net
2Proprietary Product Sales
TypeHardware Sales
Description

Sale of Nemera's own IP products including Novelia eyedroppers, Safe'n'Sound safety systems, pen injectors, pumps, and other drug delivery devices to pharmaceutical customers.

nemera.net
3Combination Product Development Services
TypeProfessional Services
Description

Comprehensive services covering the entire combination product journey including analytical services, design verification, human factors engineering, regulatory strategy, and submission authoring. These services are provided as standalone or integrated packages.

nemera.net
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing for pharmaceutical customers
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies based on device type, development stage, manufacturing volume, regulatory requirements, and service scope. No public pricing available as projects are tailored to customer needs.

nemera.net
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nemera is a global Contract Development and Manufacturing Organization (CDMO) that designs, develops, and manufactures proprietary drug delivery device solutions — including ophthalmic eyedroppers, pen and auto-injectors, safety syringes, inhalers, nasal pumps, dermal packaging, and wearable injectors — alongside combination product development, clinical and commercial manufacturing, and regulatory services for pharmaceutical, biotechnology, and generic drug customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 1 billion devices sold annually across 54 countries
+2 more records
Product overview1 text field

Nemera is a global CDMO (Contract Development and Manufacturing Organization) providing holistic drug delivery device solutions and combination product services. The company offers a comprehensive portfolio of proprietary drug delivery devices across multiple therapeutic areas: Ophthalmic (Novelia® and e-Novelia eyedroppers), Dermal (Sof'Bag®+, Sof'Airless XS+, atmospheric pumps, CRC closures), Ear Nose Throat (SP27/SP37 multidose pumps, UniSpray, DuoSpray, DriDose®, Safe'n'Spray electronic devices, nasal vaccine), Inhalation (DPI and pMDI inhalers), and Parenteral (Safe'n'Sound® passive safety systems, reusable/disposable/tailor-made pen injectors, implanters, Symbioze® on-body injector wearables). The company also provides intimate care applicators and oral administration dosers. Nemera operates as an integrated partner offering front-end innovation, device development, clinical/commercial manufacturing, and regulatory strategy services. The product portfolio is supported by manufacturing facilities in France, Germany, Poland, US, and Brazil, with over 200 innovation consultants at Insight Innovation Centers.

Product and service22 records
1Novelia® multi-dose eyedropper
CategoryOphthalmic drug delivery devices
Description

Multi-dose eyedropper with a closing tip system that prevents bacterial contamination and eliminates the need for preservatives in ophthalmic formulations. Features a patented blue tip for enhanced eye targeting and PureFlow® silicone membrane venting technology. Sold to pharmaceutical customers for ophthalmic drug products.

2e-Novelia smart ophthalmic add-on
CategoryOphthalmic drug delivery devices
Description

Smart ophthalmic add-on device that improves existing ophthalmic treatment administration to enhance patient adherence. Used by pharmaceutical customers alongside ophthalmic drug products.

3Safe'n'Sound® passive safety device (1ml and 2.25ml)
CategoryParenteral drug delivery devices
Description

Premium passive safety device platform that prevents needlestick injuries with an ergonomic design for both skilled and inexperienced users, available in 1ml and 2.25ml prefilled syringe configurations. Sold to pharmaceutical customers for injectable drugs.

4Reusable Pen Injectors
CategoryParenteral drug delivery devices
Description

Reusable pen injector platform with replaceable cartridges for multidose formulation delivery, intended for extended use over several years. Used by pharmaceutical customers for chronic conditions such as diabetes and growth hormone deficiency.

5Disposable Pen Injectors
CategoryParenteral drug delivery devices
Description

Ready-to-use prefilled disposable pen injectors with a set drug amount in the cartridge, disposed of when depleted. Used by pharmaceutical customers for single-course injectable therapies.

6Tailor-made Pens and Auto-Injectors
CategoryParenteral drug delivery devices
Description

Custom-designed pen injectors and auto-injectors tailored to customer specifications for pharmaceutical products including insulin, GLP-1, hormones, and fertility treatments.

7Symbioze® on-body wearable injector
CategoryParenteral drug delivery devices
Description

Unique on-body wearable injector for subcutaneous delivery of high-viscosity biologic formulations, with a robust, easy-to-use design intended for self-administration at home. Sold to biotechnology and pharmaceutical customers developing biologics.

8Implanters with integrated needlestick protection
CategoryParenteral drug delivery devices
Description

Devices for implant delivery with integrated needlestick protection, designed to support improved holding, priming, and motion for implant insertion by healthcare professionals and patients.

9DPI and pMDI Inhalers
CategoryInhalation drug delivery devices
Description

Pressurized Metered Dose Inhalers (pMDI) and Dry Powder Inhalers (DPI) for treating asthma and COPD, covering the full development lifecycle from concept to large-scale manufacturing. Sold to pharmaceutical customers in respiratory therapeutics.

10UniSpray single-metered dose nasal device
CategoryNasal drug delivery devices
Description

Single-metered accurate dose nasal delivery device ideal for systemic delivery in emergency life-saving and crisis treatment, particularly suitable for naloxone rescue applications.

11DuoSpray nasal delivery device
CategoryNasal drug delivery devices
Description

DuoSpray nasal delivery device designed to deliver life-saving and crisis treatments with high efficiency and robustness for nasal drug delivery.

12DriDose® dry powder intranasal platform
CategoryNasal drug delivery devices
Description

DriDose® dry powder intranasal delivery technology developed in partnership with Therakind for delivering innovative medicines, particularly life-saving and crisis treatments, via the nasal route.

13SP27 and SP37 Multidose Pump Systems
CategoryNasal and oral drug delivery devices
Description

Multidose pump systems for ear, nose and throat delivery, providing a full range of pump and valve platforms ensuring precision and dose consistency for nasal and oral drugs.

14Safe'n'Spray electronic nasal device
CategoryNasal drug delivery devices
Description

Electronic nasal drug delivery device with full design, development and manufacturing services for electronic nasal devices. Sold to pharmaceutical customers for nasal drugs requiring electronic delivery control.

15Sof'Bag®+ airless pouch-in-bottle packaging
CategoryDermal drug delivery devices
Description

Airless pouch-in-bottle packaging solution for prescription (Rx) and over-the-counter (OTC) dermal and transdermal formulations, protecting sensitive formulations from oxygen, light, and moisture.

16Sof'Airless XS+ mini-airless system
CategoryDermal drug delivery devices
Description

Protective mini-airless system for delivering gel and cream formulations in small dose applications and sampling. Used by pharmaceutical and dermocosmetic customers.

17Atmospheric spray pumps for liquid formulations
CategoryDermal drug delivery devices
Description

Atmospheric spray pumps for delivering liquid and viscous formulations across comprehensive dose ranges, suitable for regulated and less regulated markets.

18Vaginal and rectal applicators
CategoryIntimate care drug delivery devices
Description

Vaginal and rectal applicators used to treat intimate pathologies including vaginal infections, bacterial vaginosis, vaginal atrophy, hemorrhoids, and anal fissures.

19Liquid oral dosers
CategoryOral drug delivery devices
Description

Liquid delivery dosers for pediatric applications including non-narcotic analgesics, anti-acids, anti-flatulents, and medical food supplementation.

20Front-End Innovation and Device Development services
CategoryDrug delivery development services
Description

Front-end innovation, human factors research, design engineering, and device development services for pharmaceutical and biotechnology customers, delivered by the Insight by Nemera practice of 200+ consultants. Sold as standalone or integrated packages.

21Clinical and Commercial Manufacturing services
CategoryContract manufacturing services
Description

Contract development and manufacturing services covering clinical device supply, process engineering and industrialization, and commercial manufacturing for drug delivery devices and combination products, delivered from five global manufacturing facilities.

22Combination Product Services
CategoryCombination product services
Description

Comprehensive services covering the entire combination product journey including analytical services, design verification, human factors engineering, regulatory strategy, and submission authoring. Provided as standalone or integrated packages to pharmaceutical customers.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Strategic partnership to advance DriDose® dry powder intranasal technology. The partnership combines Nemera's know-how with Therakind's experience in developing and delivering innovative medicines to patients for life-saving and crisis treatments.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-01
Description

Chinese pharmaceutical company that launched lubricant eyedrops (Eyesucom®) with Nemera's Novelia® 15mL dispenser in China for contact lens discomfort and dry eye treatment. This partnership extends Novelia's global reach to the Chinese market.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership for the development of electronic drug delivery devices. Zollner supports the design, development, and manufacturing of electronic drug delivery systems for both Nemera's proprietary and customer-owned products. Collaboration begins with Nemera's existing electronic device portfolio.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in elastomeric components, injectables containment, and drug delivery devices (auto-injectors, prefilled systems). Most direct competitor to Nemera across primary packaging and combination-product device platforms serving the same Big Pharma customer base.

TypeBroad incumbent
Description

Large diversified medical technology company with broad pharmaceutical systems and drug delivery device franchises (BD Medical). Larger scale and broader portfolio than Nemera, but overlaps meaningfully in prefilled syringes, auto-injectors, and injection safety devices.

TypeDirect peer
Description

Swiss specialist in pen injectors, auto-injectors, and large-volume wearable injectors for self-medication. Direct competitor across Nemera's pen and Symbioze wearable portfolios, particularly in diabetes, GLP-1, and biotech injectables.

TypeDirect peer
Description

CDMO for medical devices and drug delivery, including injectors, inhalers, and connected health devices. Closely comparable integrated design-to-manufacture offering to Nemera's Insight + manufacturing model.

TypeDirect peer
Description

Italian-headquartered drug containment and delivery solutions provider offering glass vials, syringes, and device platforms including pen injectors and on-body delivery systems. Closest scale and product-mix comparable to Nemera.

TypeDirect peer
Description

UK-based drug delivery device specialist with proprietary auto-injector, pen, and safety platforms sold B2B to pharma. Highly comparable business model and product range to Nemera, particularly in parenteral and self-injection devices.

TypeDirect peer
Description

Pharmaceutical packaging and drug delivery device manufacturer with strong positions in prefilled syringes, auto-injectors, and inhalation devices. Directly competes with Nemera in parenteral and combination-product categories.

TypeEmerging player
Description

CDMO with growing device and inhalation business. Smaller and more drug-substance anchored than Nemera, but increasingly competes in DPI/inhalation device development and aseptic manufacturing.

TypeDirect peer
Description

Primary packaging and drug delivery arm of Schott AG, focused on glass vials, syringes, cartridges and integrated drug containment solutions. Direct competitor to Nemera in pharma primary packaging and combination-product enabling technologies.

10Recipharm (ReciBio)
TypeBroad incumbent
Description

Large pharmaceutical CDMO offering sterile fill-finish, biologics, and advanced delivery services. Overlaps with Nemera in clinical and commercial manufacturing services, though less device-specialized.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nemera

Drug Delivery Devicesnemera.net

Nemera is a France-headquartered, PE-backed CDMO designing and manufacturing proprietary drug delivery devices — eyedroppers, injectors, inhalers, and nasal systems — for global pharmaceutical, biotech, and generics customers across five manufacturing sites serving 54 countries.

What Nemera does

Nemera is a France-headquartered, privately held contract development and manufacturing organization (CDMO) specializing in drug delivery device solutions across ophthalmic, parenteral, inhalation, dermal, ear-nose-throat, oral, and intimate care administration routes. The company designs, develops, and manufactures proprietary device platforms — including the Novelia multi-dose eyedropper system with patented PureFlow silicone membrane technology, Safe'n'Sound passive needle safety devices, Symbioze on-body wearable injectors for high-viscosity biologics, Sof'Bag+ airless dermal packaging, and DPI/pMDI inhalers — alongside tailor-made pen injectors and auto-injectors. Manufacturing is conducted across five GMP-certified sites in France, Germany, Poland, the United States, and Brazil, encompassing over 42,000 square meters of clean room capacity and producing more than one billion devices annually for distribution in 54 countries.

The company operates a hybrid B2B business model combining project-based combination product development services (front-end innovation, human factors, design verification, regulatory strategy) with proprietary product sales and contract manufacturing across clinical and commercial volumes. Customers are large pharmaceutical, biotechnology, and generic drug companies — disclosed enterprise relationships include GlaxoSmithKline, SciGen, and Haohai Qisheng. Pricing is negotiated per-project under multi-year contracts and is not publicly disclosed. The Insight Innovation Center in Chicago houses over 200 innovation and device development consultants serving as Nemera's front-end innovation engine.

Nemera is jointly owned by private equity firms Montagu and Astorg (with LGT Capital Partners as a co-investor), and traces its corporate history to Rexam Healthcare before being acquired by Montagu in 2014. The company has pursued a sustained buy-and-build strategy (Insight Product Development in 2019, Copernicus in 2020, Milfra in 2021) and has stated a strategic ambition to become a billion-dollar company by 2030. The company maintains comprehensive quality certifications including ISO 13485, EU MDR, FDA 21 CFR Part 820, MDSAP, and EcoVadis Gold status for sustainability.

Nemera firmographics

Firmographics
Name
Nemera
Legal name
Financiere N
Website
https://nemera.net
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Nemera is a France-headquartered, PE-backed CDMO designing and manufacturing proprietary drug delivery devices — eyedroppers, injectors, inhalers, and nasal systems — for global pharmaceutical, biotech, and generics customers across five manufacturing sites serving 54 countries.
Ownership category
akta.pro rank

Nemera industry classification

Industry
Product category
Drug Delivery Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Drug delivery devices
  • Contract manufacturing services
  • Combination product development
  • Ophthalmic drug delivery
  • Parenteral injection devices

Where Nemera is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices8 records

Markets served

Nemera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: Nemera provides contract development and manufacturing services for drug delivery devices and combination products. This includes clinical and commercial manufacturing, process engineering, and industrialization services. Revenue is generated through project-based contracts and long-term manufacturing partnerships with pharmaceutical companies.
  2. Proprietary Product Sales: Sale of Nemera's own IP products including Novelia eyedroppers, Safe'n'Sound safety systems, pen injectors, pumps, and other drug delivery devices to pharmaceutical customers.
  3. Combination Product Development Services: Comprehensive services covering the entire combination product journey including analytical services, design verification, human factors engineering, regulatory strategy, and submission authoring. These services are provided as standalone or integrated packages.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for pharmaceutical customers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Nemera product offering

Product offering

Core offering

Nemera is a global Contract Development and Manufacturing Organization (CDMO) that designs, develops, and manufactures proprietary drug delivery device solutions — including ophthalmic eyedroppers, pen and auto-injectors, safety syringes, inhalers, nasal pumps, dermal packaging, and wearable injectors — alongside combination product development, clinical and commercial manufacturing, and regulatory services for pharmaceutical, biotechnology, and generic drug customers.

Product overview

Nemera is a global CDMO (Contract Development and Manufacturing Organization) providing holistic drug delivery device solutions and combination product services. The company offers a comprehensive portfolio of proprietary drug delivery devices across multiple therapeutic areas: Ophthalmic (Novelia® and e-Novelia eyedroppers), Dermal (Sof'Bag®+, Sof'Airless XS+, atmospheric pumps, CRC closures), Ear Nose Throat (SP27/SP37 multidose pumps, UniSpray, DuoSpray, DriDose®, Safe'n'Spray electronic devices, nasal vaccine), Inhalation (DPI and pMDI inhalers), and Parenteral (Safe'n'Sound® passive safety systems, reusable/disposable/tailor-made pen injectors, implanters, Symbioze® on-body injector wearables). The company also provides intimate care applicators and oral administration dosers. Nemera operates as an integrated partner offering front-end innovation, device development, clinical/commercial manufacturing, and regulatory strategy services. The product portfolio is supported by manufacturing facilities in France, Germany, Poland, US, and Brazil, with over 200 innovation consultants at Insight Innovation Centers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Novelia® multi-dose eyedropper Multi-dose eyedropper with a closing tip system that prevents bacterial contamination and eliminates the need for preservatives in ophthalmic formulations. Features a patented blue tip for enhanced eye targeting and PureFlow® silicone membrane venting technology. Sold to pharmaceutical customers for ophthalmic drug products.
  • e-Novelia smart ophthalmic add-on Smart ophthalmic add-on device that improves existing ophthalmic treatment administration to enhance patient adherence. Used by pharmaceutical customers alongside ophthalmic drug products.
  • Safe'n'Sound® passive safety device (1ml and 2.25ml) Premium passive safety device platform that prevents needlestick injuries with an ergonomic design for both skilled and inexperienced users, available in 1ml and 2.25ml prefilled syringe configurations. Sold to pharmaceutical customers for injectable drugs.
  • Reusable Pen Injectors Reusable pen injector platform with replaceable cartridges for multidose formulation delivery, intended for extended use over several years. Used by pharmaceutical customers for chronic conditions such as diabetes and growth hormone deficiency.
  • Disposable Pen Injectors Ready-to-use prefilled disposable pen injectors with a set drug amount in the cartridge, disposed of when depleted. Used by pharmaceutical customers for single-course injectable therapies.
  • Tailor-made Pens and Auto-Injectors Custom-designed pen injectors and auto-injectors tailored to customer specifications for pharmaceutical products including insulin, GLP-1, hormones, and fertility treatments.
  • Symbioze® on-body wearable injector Unique on-body wearable injector for subcutaneous delivery of high-viscosity biologic formulations, with a robust, easy-to-use design intended for self-administration at home. Sold to biotechnology and pharmaceutical customers developing biologics.
  • Implanters with integrated needlestick protection Devices for implant delivery with integrated needlestick protection, designed to support improved holding, priming, and motion for implant insertion by healthcare professionals and patients.
  • DPI and pMDI Inhalers Pressurized Metered Dose Inhalers (pMDI) and Dry Powder Inhalers (DPI) for treating asthma and COPD, covering the full development lifecycle from concept to large-scale manufacturing. Sold to pharmaceutical customers in respiratory therapeutics.
  • UniSpray single-metered dose nasal device Single-metered accurate dose nasal delivery device ideal for systemic delivery in emergency life-saving and crisis treatment, particularly suitable for naloxone rescue applications.
  • DuoSpray nasal delivery device DuoSpray nasal delivery device designed to deliver life-saving and crisis treatments with high efficiency and robustness for nasal drug delivery.
  • DriDose® dry powder intranasal platform DriDose® dry powder intranasal delivery technology developed in partnership with Therakind for delivering innovative medicines, particularly life-saving and crisis treatments, via the nasal route.
  • SP27 and SP37 Multidose Pump Systems Multidose pump systems for ear, nose and throat delivery, providing a full range of pump and valve platforms ensuring precision and dose consistency for nasal and oral drugs.
  • Safe'n'Spray electronic nasal device Electronic nasal drug delivery device with full design, development and manufacturing services for electronic nasal devices. Sold to pharmaceutical customers for nasal drugs requiring electronic delivery control.
  • Sof'Bag®+ airless pouch-in-bottle packaging Airless pouch-in-bottle packaging solution for prescription (Rx) and over-the-counter (OTC) dermal and transdermal formulations, protecting sensitive formulations from oxygen, light, and moisture.
  • Sof'Airless XS+ mini-airless system Protective mini-airless system for delivering gel and cream formulations in small dose applications and sampling. Used by pharmaceutical and dermocosmetic customers.
  • Atmospheric spray pumps for liquid formulations Atmospheric spray pumps for delivering liquid and viscous formulations across comprehensive dose ranges, suitable for regulated and less regulated markets.
  • Vaginal and rectal applicators Vaginal and rectal applicators used to treat intimate pathologies including vaginal infections, bacterial vaginosis, vaginal atrophy, hemorrhoids, and anal fissures.
  • Liquid oral dosers Liquid delivery dosers for pediatric applications including non-narcotic analgesics, anti-acids, anti-flatulents, and medical food supplementation.
  • Front-End Innovation and Device Development services Front-end innovation, human factors research, design engineering, and device development services for pharmaceutical and biotechnology customers, delivered by the Insight by Nemera practice of 200+ consultants. Sold as standalone or integrated packages.
  • Clinical and Commercial Manufacturing services Contract development and manufacturing services covering clinical device supply, process engineering and industrialization, and commercial manufacturing for drug delivery devices and combination products, delivered from five global manufacturing facilities.
  • Combination Product Services Comprehensive services covering the entire combination product journey including analytical services, design verification, human factors engineering, regulatory strategy, and submission authoring. Provided as standalone or integrated packages to pharmaceutical customers.

Quantifiable outcome

  • Over 1 billion devices sold annually across 54 countries
  • +2 more outcomes

Companies that use Nemera

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Nemera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Nemera partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • TherakindcoreStrategic or Co-development Partner · 1 April 2026Strategic partnership to advance DriDose® dry powder intranasal technology. The partnership combines Nemera's know-how with Therakind's experience in developing and delivering innovative medicines to patients for life-saving and crisis treatments.
  • Haohai Qisheng (Shanghai HaoHai)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2026Chinese pharmaceutical company that launched lubricant eyedrops (Eyesucom®) with Nemera's Novelia® 15mL dispenser in China for contact lens discomfort and dry eye treatment. This partnership extends Novelia's global reach to the Chinese market.
  • ZollnercoreTechnology or IntegrationPartnership for the development of electronic drug delivery devices. Zollner supports the design, development, and manufacturing of electronic drug delivery systems for both Nemera's proprietary and customer-owned products. Collaboration begins with Nemera's existing electronic device portfolio.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Nemera competitors and assessment

Company assessment

Direct peers

  • West Pharmaceutical Services: Global leader in elastomeric components, injectables containment, and drug delivery devices (auto-injectors, prefilled systems). Most direct competitor to Nemera across primary packaging and combination-product device platforms serving the same Big Pharma customer base.
  • Ypsomed Holding AG: Swiss specialist in pen injectors, auto-injectors, and large-volume wearable injectors for self-medication. Direct competitor across Nemera's pen and Symbioze wearable portfolios, particularly in diabetes, GLP-1, and biotech injectables.
  • Phillips-Medisize (a Molex company): CDMO for medical devices and drug delivery, including injectors, inhalers, and connected health devices. Closely comparable integrated design-to-manufacture offering to Nemera's Insight + manufacturing model.
  • Stevanato Group: Italian-headquartered drug containment and delivery solutions provider offering glass vials, syringes, and device platforms including pen injectors and on-body delivery systems. Closest scale and product-mix comparable to Nemera.
  • Owen Mumford: UK-based drug delivery device specialist with proprietary auto-injector, pen, and safety platforms sold B2B to pharma. Highly comparable business model and product range to Nemera, particularly in parenteral and self-injection devices.
  • Gerresheimer AG: Pharmaceutical packaging and drug delivery device manufacturer with strong positions in prefilled syringes, auto-injectors, and inhalation devices. Directly competes with Nemera in parenteral and combination-product categories.
  • Schott Pharma: Primary packaging and drug delivery arm of Schott AG, focused on glass vials, syringes, cartridges and integrated drug containment solutions. Direct competitor to Nemera in pharma primary packaging and combination-product enabling technologies.

Broad incumbents

  • Becton, Dickinson and Company (BD): Large diversified medical technology company with broad pharmaceutical systems and drug delivery device franchises (BD Medical). Larger scale and broader portfolio than Nemera, but overlaps meaningfully in prefilled syringes, auto-injectors, and injection safety devices.
  • Recipharm (ReciBio): Large pharmaceutical CDMO offering sterile fill-finish, biologics, and advanced delivery services. Overlaps with Nemera in clinical and commercial manufacturing services, though less device-specialized.

Emerging players

  • Hovione: CDMO with growing device and inhalation business. Smaller and more drug-substance anchored than Nemera, but increasingly competes in DPI/inhalation device development and aseptic manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Nemera social profiles

Digital presence

Nemera compliance and trust

Trust signal

Compliance11 records

Nemera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nemera leadership team

Management profile

Number of profiles

Profiles9 records

Nemera subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Nemera funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nemera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nemera

What does Nemera do?

Nemera is a global Contract Development and Manufacturing Organization (CDMO) that designs, develops, and manufactures proprietary drug delivery device solutions — including ophthalmic eyedroppers, pen and auto-injectors, safety syringes, inhalers, nasal pumps, dermal packaging, and wearable injectors — alongside combination product development, clinical and commercial manufacturing, and regulatory services for pharmaceutical, biotechnology, and generic drug customers.

Is Nemera a public or private company?

Nemera is a private company. It is classified as private equity controlled and is currently operating.

When was Nemera founded?

Nemera was founded in 2014. It employs 1,001 to 5,000 people.

Where is Nemera based?

Nemera is headquartered in Lyon, France, in the Europe region.

How does Nemera make money?

Three revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are proprietary Product Sales and combination Product Development Services.

Who are Nemera's main competitors?

Direct peers on record are West Pharmaceutical Services, Ypsomed Holding AG, Phillips-Medisize (a Molex company), Stevanato Group, Owen Mumford, Gerresheimer AG and Schott Pharma. Broad incumbents are Becton, Dickinson and Company (BD) and Recipharm (ReciBio). Hovione is listed as an emerging player.

Does Nemera have an API?

No public API is recorded for Nemera.

What industry is Nemera in?

Nemera's product category is Drug Delivery Devices. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestNemera's Owners Want €3 Billion for a Drug Pen Maker. Here's Why That Multiple Is the Whole Story.Nemera's private equity owners, Astorg Partners and Montagu Private Equity, are consulting advisers on a sale that could value the drug-delivery device maker at roughly €3 billion, or about $3.3 billion. At roughly €138 million EBITDA, that implies about 22x EBITDA, between peers West Pharmaceutical and Aptar, despite a B- credit rating and about €1 billion of debt.BloombergGLP-1 Pen Maker Nemera Could Be Sold for €3 Billion, Sources Say - BloombergPrivate equity owners of Nemera, which makes delivery devices for popular weight-loss drugs, are in early talks about selling their majority stake, according to people familiar with the matter. Astorg Partners and Montagu Private Equity are consulting advisers on a potential sale valued at roughly €3 billion ($3.5 billion). The process is expected to begin in the coming months.MoonfareCo-Investments in private markets: More control, lower fees, better returns?Co-investments and direct investments have become a core component of diversified private markets portfolios for a wide range of investors, offering targeted exposure with lower fees, greater transparency, and more control than traditional fund investments. The market for co-investments has grown significantly, with dedicated co-investment funds raising a record $43.4 billion in 2025 and AUM reaching nearly $400 billion, according to PitchBook data. Examples of major co-investment deals include Silverlake's $12.5 billion acquisition of Qualtrics, Montagu and Astorg's follow-on capital to Nemera with LGT Capital Partners as co-investor, and EQT's $14.5 billion purchase of Nord Anglia Education with Neuberger Berman as strategic co-investor.pharmaphorumTrends & Insights, January 2026: A pharmaphorum industry reportPharmaphorum's January 2026 Trends & Insights report covers major life sciences developments including Life Biosciences securing FDA IND clearance for ER 100 (partial epigenetic reprogramming therapy entering first-in-human Phase 1 for optic neuropathies), Complement Therapeutics receiving Fast Track designation for CTx001 in geographic atrophy, and Incyte obtaining positive CHMP opinion for Zynyz as first-line SCAC treatment. The report also highlights AI-driven advances in therapeutic design with Basecamp Research's EDEN platform achieving 97% wet lab success rates, manufacturing innovations from ACG and Nemera improving packaging efficiency, and continued oncology activity across multiple mechanisms including ADCs and BTK degraders.Industry EMEAMitutoyo and Nemera: a partnership in pharmaceutical device precisionNemera is enhancing its pharmaceutical device manufacturing capabilities through a partnership with Mitutoyo, involving advanced measurement and inspection technology at its Neuenburg site in Germany. The collaboration centers on a new high-resolution computed tomography system from RX Solutions, which will improve the precision of drug delivery systems. Nemera's commitment to quality ensures that every dispenser produced meets strict legal and industry standards across its six global production sites.NemeraNemera launches a reusable auto-injector at CPHI MilanNemera, a drug delivery device manufacturer, said it will present a reusable auto-injector platform for the first time at CPHI Worldwide in Milan in October. The company, which derives 44% of its revenue from injection devices, cited sustainability and demand for larger injection volumes as key trends, with its Symbioze wearable platform delivering up to 20 ml.NewswireIIROC Trading Halt - NEME.PIIROC halted trading in New Media Capital 2.0 Inc. (NEME.P) on the TSX-Venture on Dec. 23, 2021, at 8:00 a.m. ET, citing a pending closing. The halt is a temporary suspension to ensure a fair and orderly market.Law360Ex-Exec Gets 2 Years For $5.8M Fraud With Escort GirlfriendA former Illinois executive was sentenced to 25 months in prison for fraud involving $5.8 million of his former employer's money. He used a company credit card to buy jewelry, San Diego housing, and other luxuries for his escort-turned-girlfriend.Healthcare Packaging2020 Pharmapack Award Winners AnnouncedPharmapack Europe announced eight 2020 award winners across Exhibitor Innovations and Health Products categories. Credence MedSystems and NEMERA won Best Innovation in Drug Delivery Device, while Huhtamaki and PACKSYS won Primary Packaging. Abbott Healthcare and Boehringer Ingelheim won Patient-centric Design and Eco-design, respectively.